Intermittent Treatment to Prevent Pregnancy Malaria Does Not Confer Benefit in an Area of Widespread Drug Resistance | Zendy

Whitney E. Harrington | Zendy; Theonest K. Mutabingwa | Zendy; Edward Kabyemela | Zendy; M. Fried | Zendy; Patrick E. Duffy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intermittent Treatment to Prevent Pregnancy Malaria Does Not Confer Benefit in an Area of Widespread Drug Resistance

Author(s) -

Whitney E. Harrington,

Theonest K. Mutabingwa,

Edward Kabyemela,

M. Fried,

Patrick E. Duffy

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir376

Subject(s) - medicine , malaria , pregnancy , drug resistance , drug , intensive care medicine , resistance (ecology) , pharmacology , immunology , microbiology and biotechnology , ecology , biology , genetics

Millions of African women receive sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment during pregnancy (IPTp) to avoid poor outcomes that result from malaria. However, parasites resistant to SP are widespread in parts of Africa, and IPTp may perversely exacerbate placental infections that contain SP-resistant parasites.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research